Where does Psioxus Therapeutics Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Psioxus Therapeutics Limited ranks #19,046 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Psioxus Therapeutics Limited hold?

Psioxus Therapeutics Limited holds 15 US utility patents granted between 2015 and 2022, spanning 5 technology areas.

What is Psioxus Therapeutics Limited's Innovation Score?

Psioxus Therapeutics Limited has an Innovation Score of 28.4 out of 100 (27th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Psioxus Therapeutics Limited's patent grant rate increasing or decreasing?

Psioxus Therapeutics Limited's recent grant velocity is -12% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Psioxus Therapeutics Limited's patents?

Psioxus Therapeutics Limited's patents average 16.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Psioxus Therapeutics Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Psioxus Therapeutics Limited

Q: What technology areas does Psioxus Therapeutics Limited focus on?

Psioxus Therapeutics Limited's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 15 patents, ranking #709 of 4,144 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

USPTO PatentsView assignee record - 15 granted patents across 5 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Psioxus ranks #19,046 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 5 technology areas.

#19,046
of 49,997 US assignees by volume: 27th percentile
by Innovation Score (28.4/100): 16.9
avg claims per patent: -12%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19046 · Foreign Corporation #19,046 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #19,046/49,997
PHOTO-FINISH Preciflex
CPC-NARROW C12N · 5 areas
INNOV-THIN 28.4/100
CLAIMS-RICH 16.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -12% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Preciflex SA (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Psioxus’s 28.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (34%) Velocity 0.8 pts (3%) Breadth 7.9 pts (28%) Claim depth 10.1 pts (36%)

Qualcomm Incorporated · highest

85
Psioxus Therapeutics · this assignee

28
3D Lighting… · lowest

7

What this shows Psioxus's Innovation Score is 28.4/100 (27th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Psioxus?

Each dot is one of Psioxus’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Psioxus’s own 16.9 claims/patent is ABOVE the 13.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Psioxus vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Psioxus's grants concentrate

Psioxus Therapeutics Limited is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2021 (4 grants) versus a trough of 1 in 2016. By volume, Psioxus sits between Preciflex SA and PTI Marketing Technologies Inc..

Psioxus's three-year grant acceleration

Psioxus Therapeutics Limited shows 1 grants in 2022–2024 against only 8 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Preciflex

15
Probi AB

15
Prometheus Biosci…

15
PRS Medical

15
PT ESG NEW Energy…

15
PT GEM Indonesia…

15
PT QMB NEW Energy…

15
PTI Marketing

15
Psioxus Therapeut… ◀

15

What this shows Psioxus holds 15 patents at rank #19,011, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Psioxus

By rank, the assignees closest to #19,011 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Psioxus's primary technology class.

Psioxus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 27th percentile higher than 27% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Psioxus Therapeutics Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	13.3%
2016	1	6.7%
2018	3	20.0%
2019	2	13.3%
2020	2	13.3%
2021	4	26.7%
2022	1	6.7%

Which technologies does Psioxus Therapeutics Limited patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 15

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 15

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 13

C07K - Peptides 7

Y02A - Technologies FOR Adaptation TO Climate Change 2

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Psioxus Therapeutics Limited's patent record in context - here's where to go next.

Psioxus Therapeutics Limited's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #19,046 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Psioxus Therapeutics Limited against Preciflex SA, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 28.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.